Boston Scientific (NYSE:BSX) Stock Price Up 4% – What’s Next?

Boston Scientific Corporation (NYSE:BSX) shares shot up 4% on Monday . The company traded as high as $48.62 and last traded at $48.7370. 4,676,513 shares changed hands during trading, a decline of 75% from the average daily volume of 18,425,279 shares. The stock had previously closed at $46.84.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Jefferies Financial Group cut their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, Barclays cut their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Price Performance

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market cap of $69.93 billion, a P/E ratio of 19.53, a P/E/G ratio of 1.02 and a beta of 0.56. The company’s 50 day simple moving average is $46.56 and its 200 day simple moving average is $56.53.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm posted $0.75 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 194,522 shares of company stock worth $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $5,534,781,000. California State Teachers Retirement System raised its holdings in shares of Boston Scientific by 4,113.5% during the second quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider’s stock worth $4,136,078,000 after acquiring an additional 94,609,083 shares during the period. Primecap Management Co. CA acquired a new stake in shares of Boston Scientific during the second quarter worth $2,156,233,000. Norges Bank bought a new stake in Boston Scientific in the 4th quarter valued at $2,199,395,000. Finally, Jupiter Topco LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $803,357,000. 89.07% of the stock is owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.